Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting.
about
Update on hepatitis C: Direct-acting antiviralsThe impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis.Prioritization for interferon-free regimens and potential drug interactions of current direct-acting anti-hepatitis C agents in routine clinical practice.Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.Long-term outcome of chronic hepatitis C virus infection in a real-world setting: The German LOTOS study.Direct antiviral agent treatment of decompensated hepatitis C virus-induced liver cirrhosisPrognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era.Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies.Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort.Real-world effect of ribavirin on quality of life in HCV-infected patients receiving interferon-free treatment.Going Viral: Why Eliminating the Burden of Hepatitis C Requires Enhanced Cooperation Between Specialists and Primary Care Providers.
P2860
Q26775809-43D345F0-FF2A-4CB6-91A9-531A8200CE21Q30250096-FA543137-EC1F-46DC-9149-BCF5296F3DAEQ38398290-A22D7EF1-AA27-4F8F-96BF-519EBBFE54F1Q38606309-84A9A235-98C8-4533-B745-3373D4EBA273Q38703524-A766C260-E9E1-4839-98FD-F8F837EFEDF6Q38929010-2182539A-59B6-4AD4-997D-015A08774335Q38936212-02BF7EF7-3657-4C69-9338-97935F65BEE6Q40333567-580803D2-D36E-49F4-8249-6CCA21CC23EBQ40436361-7784C400-DB08-4282-91FA-2232F0E1CAA0Q41065311-840FECA4-3096-477E-9631-3273E91B0CCFQ41092963-57D8F041-A1AB-42DE-A3C2-32573DF00561Q41928089-03D01B4F-9DED-40F8-A151-11F18D6B2220Q46257792-B37D29DE-9599-4FCA-839E-82BC2A38D10A
P2860
Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Eligibility and safety of the ...... tis C in a real-world setting.
@en
type
label
Eligibility and safety of the ...... tis C in a real-world setting.
@en
prefLabel
Eligibility and safety of the ...... tis C in a real-world setting.
@en
P2093
P2860
P356
P1433
P1476
Eligibility and safety of the ...... tis C in a real-world setting.
@en
P2093
Carola Mix
Christoph Höner Zu Siederdissen
Heiner Wedemeyer
Janet Cornberg
Janina Kirschner
Katja Deterding
Kerstin Port
Lisa Sollik
Markus Cornberg
Michael P Manns
P2860
P304
P356
10.1111/LIV.12774
P577
2015-02-02T00:00:00Z